Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by electrowingon Nov 13, 2012 12:06pm

178 Views

Post# 20593652

RE: RE: RE: Valuation ?

maybe you're right ~ my platform stats show 14,007,855 (identical) in both markets, NSD & TSX. So, maybe it's just showing the total float for both exchanges. In that case, my guess is TKM is worth closer to $7 SP than $6 on the cash influx.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?